Dinutuximab - Biologic Drug Details

Summary for dinutuximab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for dinutuximab

Recent Clinical Trials for dinutuximab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Jubilant DraxImage Inc.	PHASE2
Tianjin Medical University Cancer Institute and Hospital	PHASE2
National Cancer Institute (NCI)	PHASE1

See all dinutuximab clinical trials

Pharmacology for dinutuximab

Mechanism of Action	Glycolipid Disialoganglioside-directed Antibody Interactions
Established Pharmacologic Class	Glycolipid Disialoganglioside-directed Antibody

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for dinutuximab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for dinutuximab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
United Therapeutics Corporation	UNITUXIN	dinutuximab	Injection	125516	10,034,914	2037-03-16	DrugPatentWatch analysis and company disclosures
United Therapeutics Corporation	UNITUXIN	dinutuximab	Injection	125516	10,246,547	2032-10-03	DrugPatentWatch analysis and company disclosures
United Therapeutics Corporation	UNITUXIN	dinutuximab	Injection	125516	10,512,686	2039-02-28	DrugPatentWatch analysis and company disclosures
United Therapeutics Corporation	UNITUXIN	dinutuximab	Injection	125516	10,632,234	2037-01-13	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for dinutuximab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
United Therapeutics Corporation	UNITUXIN	dinutuximab	Injection	125516	10,072,065	2036-08-24	Patent claims search
United Therapeutics Corporation	UNITUXIN	dinutuximab	Injection	125516	10,220,072	2037-12-06	Patent claims search
United Therapeutics Corporation	UNITUXIN	dinutuximab	Injection	125516	10,265,291	2037-02-13	Patent claims search
United Therapeutics Corporation	UNITUXIN	dinutuximab	Injection	125516	10,328,157	2037-02-03	Patent claims search

International Patents for dinutuximab

Country	Patent Number	Estimated Expiration
Australia	2007285976
Spain	2940686
Cyprus	1115166
Australia	2005227326

Supplementary Protection Certificates for dinutuximab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
25/2023	Austria		PRODUCT NAME: ENTFETTETES PULVER VON ARACHIS HYPOGAEA L. SAMEN (ERDNUESSE); REGISTRATION NO/DATE: EU/1/20/1495 (MITTEILUNG) 20201221
122022000010	Germany		PRODUCT NAME: TAFASITAMAB; REGISTRATION NO/DATE: EU/1/21/1570 20210826
2022C/506	Belgium		PRODUCT NAME: TAFASITAMAB; AUTHORISATION NUMBER AND DATE: EU/1/21/1570 20210901
5/2022	Austria		PRODUCT NAME: TAFASITAMAB; REGISTRATION NO/DATE: EU/1/21/1570 (MITTEILUNG) 20210901

Dinutuximab: Market Dynamics and Financial Trajectory Analysis

Last updated: February 19, 2026

Dinutuximab is a chimeric monoclonal antibody targeting GD2, a disialoganglioside expressed on neuroblastoma cells. Its primary indication is in the treatment of high-risk neuroblastoma in pediatric patients. The drug's market trajectory is shaped by its specific therapeutic niche, regulatory exclusivities, and ongoing clinical development.

What is the Current Market Status of Dinutuximab?

Dinutuximab, marketed as Unituxin, holds Orphan Drug Designation in the United States and Europe, granting it market exclusivity periods.

• United States: Approved by the U.S. Food and Drug Administration (FDA) in March 2015. Orphan Drug Exclusivity (ODE) provides seven years of market exclusivity from the approval date, expiring in March 2022. However, additional exclusivity periods may apply. For instance, a New Chemical Entity (NCE) status can grant ten years, while a biosimilar approval would necessitate demonstrating no biosimilarity for 12 years from the reference product's approval. Dinutuximab's approval date indicates it falls within this framework.
• European Union: Approved by the European Medicines Agency (EMA) in September 2015. It benefits from ten years of data exclusivity.
• Key Competitors: While dinutuximab is a standalone therapeutic in its specific niche for high-risk neuroblastoma, the competitive landscape can be considered in terms of alternative treatment modalities. These include chemotherapy regimens, immunotherapy approaches, and radiopharmaceutical agents, though direct head-to-head comparisons are limited for its primary indication.

What are the Key Patent Expiries and Potential Patent Challenges for Dinutuximab?

The patent landscape for dinutuximab is critical for understanding its long-term market exclusivity and the potential for generic or biosimilar entry.

• Composition of Matter Patents: These patents typically cover the active pharmaceutical ingredient itself and are generally the strongest form of protection. The initial patents covering the dinutuximab molecule likely expired or are nearing expiry. Patent families associated with dinutuximab, as with most biologics, are complex and often involve multiple patents covering the molecule, its manufacturing process, and its uses.
• Manufacturing Process Patents: These patents protect the specific methods used to produce dinutuximab. Process patents can extend exclusivity for a biologic even after composition of matter patents expire, as a biosimilar manufacturer would need to develop a non-infringing process.
• Method of Use Patents: Patents covering specific therapeutic indications or dosing regimens can also provide extended market protection.
• Patent Expiries: Precise patent expiry dates are proprietary information and often subject to litigation. However, for a drug approved in 2015, the core composition of matter patents would likely have been filed in the late 1990s or early 2000s, suggesting potential expiry in the 2020s. U.S. patent law provides for patent term extension (PTE) to compensate for regulatory review delays, and restoration of patent term (RPT) for certain delays in examination. These extensions can add several years to the effective patent life.
• Potential Challenges: Biosimilar developers continuously monitor patent expiry and challenge existing patents through litigation or by seeking to invalidate them. Such challenges can lead to earlier market entry for biosimilars if successful.

What is the Financial Performance and Revenue Generation of Dinutuximab?

Dinutuximab's financial performance is tied to its specific patient population and reimbursement landscape.

• Revenue Figures: Detailed, up-to-the-minute revenue figures for dinutuximab are often reported by its manufacturer, represented by publicly available financial statements or investor relations reports. For example, in fiscal year 2022, neuroblastoma treatment revenue was reported to be $284.7 million. [1] This figure represents the cumulative sales of dinutuximab.
• Pricing Strategy: The pricing of Orphan Drugs is typically high due to the limited patient population and the significant R&D investment required. Dinutuximab's price is reflective of this, positioning it as a high-value therapeutic.
• Reimbursement Landscape: Reimbursement for dinutuximab is primarily secured through national health systems and private insurance in target markets. Payer policies and coverage decisions significantly influence market access and sales volume. The favorable reimbursement environment for orphan drugs in developed markets supports its financial performance.

What are the Ongoing Clinical Trials and Future Development Prospects for Dinutuximab?

The future trajectory of dinutuximab is influenced by ongoing research exploring its efficacy in new indications or combinations.

• Expansion to Other Indications: Research is exploring dinutuximab's potential in other GD2-expressing cancers, such as melanoma, glioblastoma, and other pediatric solid tumors. Clinical trials are underway to evaluate its safety and efficacy in these expanded settings.
  • Melanoma: Trials have investigated dinutuximab in combination with other immunotherapies for metastatic melanoma.
  • Glioblastoma: Early-phase studies are evaluating its use in recurrent glioblastoma.
• Combination Therapies: Evaluating dinutuximab in combination with other therapeutic agents, including chemotherapy, targeted therapies, and other immunotherapies (e.g., checkpoint inhibitors), is a key area of clinical investigation. These combinations aim to enhance anti-tumor activity and overcome resistance mechanisms.
• Manufacturing Improvements: As with any biologic, ongoing efforts to optimize manufacturing processes could lead to cost reductions or improved product consistency, indirectly impacting its long-term market viability.

What are the Key Regulatory Considerations and Approvals for Dinutuximab?

Regulatory approvals are foundational to dinutuximab's market access and commercialization.

• Initial Approval: FDA approval in March 2015 for high-risk neuroblastoma in patients who are responders to induction therapy. EMA approval in September 2015 for the same indication.
• Orphan Drug Designation: This designation provides incentives, including market exclusivity and tax credits, for drugs treating rare diseases. Dinutuximab holds this status in both the U.S. and EU.
• Pediatric Study Plans (PSPs): The FDA requires manufacturers of certain drugs to conduct studies in pediatric populations. Dinutuximab's development pathway included fulfilling these requirements.
• Post-Marketing Commitments: Regulatory agencies often require post-marketing studies to further evaluate safety, efficacy, or long-term outcomes. These can influence label updates and market perception.

What is the Competitive Landscape and Threat of Biosimilars for Dinutuximab?

The threat of biosimilars for biologics like dinutuximab is a significant factor in long-term market planning.

• Biosimilar Development: While dinutuximab is a targeted therapy for a rare cancer, the potential for biosimilar development exists as patent exclusivity wanes. Biosimilar manufacturers would need to demonstrate analytical, clinical, and non-clinical similarity to the reference product.
• Challenges to Biosimilar Entry: The complexity of monoclonal antibody manufacturing and the specific therapeutic niche can present higher barriers to entry for biosimilar developers compared to small molecule drugs. Demonstrating equivalent efficacy and safety in a rare pediatric cancer population can be particularly challenging and costly.
• Current Biosimilar Landscape: As of current information, there are no approved biosimilars for dinutuximab. The timeline for biosimilar development and approval is typically several years.
• Impact of Biosimilars: The introduction of biosimilars typically leads to price competition and increased market access, which can reduce revenue for the originator product. However, the specialized nature of dinutuximab's indication and the potential for continued innovation by the originator might mitigate some of this impact.

Key Takeaways

Dinutuximab's market is defined by its critical role in treating high-risk neuroblastoma, supported by orphan drug designations and associated market exclusivities. Its financial performance, evidenced by significant annual revenue, reflects its premium pricing within a specialized therapeutic niche. Ongoing clinical trials exploring expanded indications and combination therapies offer potential avenues for future growth. The patent landscape, while complex, is a key determinant of its long-term market protection against potential biosimilar entrants, which currently do not exist for dinutuximab.

Frequently Asked Questions

1. What is the primary mechanism of action for dinutuximab? Dinutuximab functions as a monoclonal antibody that targets the GD2 disialoganglioside antigen present on the surface of neuroblastoma cells and other tumor types.
2. Which regulatory bodies have approved dinutuximab, and for what indication? The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved dinutuximab for the treatment of high-risk neuroblastoma in pediatric patients.
3. How do orphan drug designations impact dinutuximab's market exclusivity? Orphan drug designations grant extended periods of market exclusivity in the U.S. and EU, preventing regulatory approval of similar products for the same indication.
4. What are the main challenges in developing a biosimilar for dinutuximab? Key challenges include the complexity of manufacturing monoclonal antibodies, demonstrating analytical and clinical similarity in a specific rare disease population, and navigating a complex patent landscape.
5. Are there any ongoing clinical trials investigating dinutuximab for indications beyond neuroblastoma? Yes, clinical trials are actively exploring dinutuximab's efficacy in other GD2-expressing cancers, including melanoma and glioblastoma, often in combination with other therapies.

Citations

1. United Therapeutics Corporation. (2023). 2022 Annual Report on Form 10-K. [Retrieved from SEC EDGAR Database]